Fig. 1From: Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinibGenomic landscape of 66 patients who underwent tissue or pleural effusion sequencing. Baseline mutations and SCNAs of the most frequently changed genes were detected by next-generation sequencing of 66 patients with EGFR-mutant NSCLC prior to Osimertinib treatmentBack to article page